1. Home
  2. Analysis
  3. Intron-a
  4. Targretin

Intron a and Targretin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Intron a and Targretin. Common interactions include diarrhoea among females and abdominal pain upper among males.

The phase IV clinical study analyzes what interactions people who take Intron a and Targretin have. It is created by eHealthMe based on reports of 12 people who take Intron a and Targretin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 16, 2022

12 people who take Intron a and Targretin together, and have interactions are studied.

What is Intron a?

Intron a has active ingredients of interferon alfa-2b. eHealthMe is studying from 9,291 Intron a users for its effectiveness, alternative drugs and more.

What is Targretin?

Targretin has active ingredients of bexarotene. eHealthMe is studying from 984 Targretin users for its effectiveness, alternative drugs and more.

Number of Intron a and Targretin reports submitted per year:

Intron a and Targretin drug interactions.

Common Intron A and Targretin drug interactions by gender *:

female:

  1. Diarrhoea
  2. Fungal infection
  3. Rash
  4. White blood cell count decreased

male:

  1. Abdominal pain upper
  2. Poor quality sleep
  3. Ocular discomfort
  4. Pruritus
  5. Skin atrophy
  6. Skin discolouration
  7. Skin exfoliation
  8. Skin fissures
  9. Skin irritation
  10. Application site inflammation

Common Intron A and Targretin drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. White blood cell count decreased

50-59:

  1. Application site inflammation
  2. Blister
  3. Dry skin
  4. Pruritus
  5. Skin atrophy
  6. Skin exfoliation
  7. Skin fissures

60+:

  1. Application site pain
  2. Application site pruritus

Common conditions people have *:

  1. Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 7 people, 58.33%
  2. T-Cell Lymphoma (a blood cell cancer): 1 person, 8.33%
  3. Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 1 person, 8.33%
  4. Neoplasm Skin (skin tumour): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Intron a and Targretin?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Intron a and Targretin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Intron a side effects:

Browse all side effects of Intron a:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Intron a interactions:

Browse all interactions between Intron a and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Targretin interactions:

Browse all interactions between Targretin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on interferon alfa-2b and bexarotene (the active ingredients of Intron a and Targretin, respectively), and Intron a and Targretin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Intron a and Targretin.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.